Thymosin Beta-4 molecular structure
Thymosin Beta-4 molecular structure
Experimental
💪Tissue Repair

Thymosin Beta-4

Also known as: TB4, Tβ4, Thymosin β4

MW

4963.44 Da

Formula

C212H350N56O78S

CAS

77591-33-4

Routes

1 route

Thymosin Beta-4 (Tβ4) is a 43-amino acid, naturally occurring peptide and the most abundant member of the beta-thymosin family. Originally isolated from the thymus gland, Tβ4 is found in virtually all nucleated cells and is particularly concentrated in blood platelets, wound fluid, and developing tissues. It is the endogenous form of TB-500 and serves as the primary intracellular G-actin sequestering protein, fundamentally regulating cytoskeletal dynamics. Tβ4 plays essential roles in embryonic development (cardiac, vascular, and neural morphogenesis) and adult tissue repair. Its central actin-binding motif LKKTETQ drives cell migration, angiogenesis, and wound healing across virtually all tissue types. RegeneRx Biopharmaceuticals has advanced Tβ4 through clinical trials for cardiac repair, wound healing, and ophthalmological applications, making it one of the most clinically studied regenerative peptides.

Research Use OnlyFor educational and research purposes only

Research Applications

Cardiac Repair

Phase 1/2 clinical trials by RegeneRx for myocardial infarction recovery. Reduces infarct size, improves ejection fraction, activates cardiac progenitor cells.

Wound Healing

Clinical trials for dermal wound healing and corneal injuries. Accelerates healing through cell migration, angiogenesis, and collagen deposition.

Ophthalmology

RGN-259 (Tβ4 eye drops) completed Phase 3 clinical trials for dry eye disease and neurotrophic keratopathy, showing improved corneal healing and symptom relief.

Musculoskeletal Repair

Preclinical studies demonstrate accelerated tendon, ligament, and muscle repair through satellite cell activation and collagen organization.

Mechanism of Action

Tβ4 sequesters G-actin monomers through the LKKTETQ domain, regulating actin polymerization dynamics essential for cell migration, division, and morphological changes. It promotes angiogenesis through VEGF and Ang1/Tie2 upregulation. Anti-inflammatory effects via NF-κB inhibition reduce tissue damage. Akt/protein kinase B activation provides cardioprotection and cell survival signaling. Tβ4 also activates resident stem/progenitor cells in cardiac, skeletal muscle, and epithelial tissues.

Biological Pathways

Akt/mTOR survival pathway. VEGF/Ang1 angiogenic signaling. HIF-1α hypoxia response. NF-κB inflammatory regulation. Wnt/β-catenin stem cell activation.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Typical Dose
750 mcg
Dose Range
300 - 1,000 mcg
Frequency
Once daily, cycle 3 months on / 6 weeks off
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Tβ4 is supplied as lyophilized powder. Store at -20°C for long-term stability. The N-terminal acetylation protects against aminopeptidase degradation. Reconstitute with bacteriostatic water, store at 2-8°C, use within 21 days. Susceptible to methionine oxidation.

Side Effects & Precautions

Generally well-tolerated in clinical trials. Mild injection site reactions. Transient lightheadedness. Theoretical cancer concern due to pro-migratory and pro-angiogenic properties, though no evidence from clinical studies. Limited long-term human safety data.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Experimental

Investigational. Phase 2/3 clinical trials completed for ophthalmological and cardiac applications (RegeneRx Biopharmaceuticals). Not FDA-approved. WADA-prohibited under S2 category.

Research Studies

Thymosin Beta 4: A Multi-Functional Regenerative Peptide

Goldstein AL, Hannappel E, Sosne G, Kleinman HK.

Expert Opinion on Biological Therapy
2012
View Source

Thymosin β4 Activates Cardiac Progenitor Cells

Smart N, Risebro CA, Melville AA, et al.

Nature
2007
View Source

RGN-259 (Thymosin β4) for Dry Eye Disease

Sosne G, Ousler GW.

Clinical Ophthalmology
2015
View Source

Thymosin β4 in Wound Healing

Malinda KM, Sidhu GS, Mani H, et al.

Journal of Investigative Dermatology
1999
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Thymosin Beta-4.
Explore More
Explore more peptides in the Tissue Repair category and related research.